Mon panier

Human IL-10 R alpha / CD210 Protein, Fc Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
ILR-H525a-100ug
$340.00
ILR-H525a-1mg
$2500.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    Interleukin-10 receptor subunit alpha, IL-10 receptor subunit alpha, IL-10R subunit alpha, IL-10RA, CDw210a, Interleukin-10 receptor subunit 1, IL-10R subunit 1, IL-10R1, CD210, IL10RA, IL10R

  • Source

    Human IL-10 R alpha Protein, Fc Tag (ILR-H525a) is expressed from human 293 cells (HEK293). It contains AA His 22 - Asn 235 (Accession # Q13651).

    Predicted N-terminus: His 22

    Request for sequence
  • Molecular Characterization

    IL-10 R alpha Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 50.8 kDa. The protein migrates as 65-75 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    IL-10 R alpha SDS-PAGE

    Human IL-10 R alpha Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    IL-10 R alpha SEC-MALS

    The purity of Human IL-10 R alpha Protein, Fc Tag (Cat. No. ILR-H525a) is more than 85% and the molecular weight of this protein is around 125-150 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     IL-10 R alpha ELISA

    Immobilized Human IL-10, His Tag (Cat. No. IL0-H4248) at 5 μg/mL (100 μL/well) can bind Human IL-10 R alpha / CD210, Fc Tag (Cat. No. ILR-H525a) with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol
  • Bioactivity-BLI

     IL-10 R alpha BLI

    Loaded Human IL-10 R alpha / CD210, Fc Tag (Cat. No. ILR-H525a) on Protein A Biosensor, can bind Human IL-10, His Tag (Cat. No. IL0-H4248) with an affinity constant of 1.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Interleukin-10 receptor subunit alpha (IL-10 R alpha ) is a cell surface receptor for the cytokine IL-10 that participates in IL-10 mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Upon binding to IL10, induces a conformational change in IL10RB, allowing IL10RB to bind IL10 as well.In turn, the heterotetrameric assembly complex, composed of two subunits of IL10RA and IL10RB, activates the kinases JAK1 and TYK2 that are constitutively associated with IL10RA and IL10RB respectively.These kinases then phosphorylate specific tyrosine residues in the intracellular domain in IL10RA leading to the recruitment and subsequent phosphorylation of STAT3.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Interleukin 10 receptor

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    9 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte